Screener
Immunome IMNM Business Segments — Other Direct Research And Development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept imnm:OtherDirectResearchAndDevelopment.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| IM-1021 | 3,864 | 3,067 |
| IM-3050 | 1,307 | 1,033 |
| IM-1617 | 838 | 375 |
| Other direct research and development | 9,971 | 4,673 |
| Indirect research and development(2) | 16,314 | 10,337 |
| General and administrative(3) | 8,649 | 7,376 |
| Other segment expenses(4) | 8,556 | 6,314 |
| Total operating expenses | 59,331 | 47,562 |
Item 1. Financial Statements.
FAQ
- What is Immunome's business segments — other direct research and development?
- Immunome (IMNM) reported business segments — other direct research and development of $9.97M in Q1 2026.
- How has Immunome's business segments — other direct research and development changed year-over-year?
- Immunome's business segments — other direct research and development increased by 113.4% year-over-year, from $4.67M to $9.97M.
- What does business segments — other direct research and development mean?
- Includes miscellaneous direct costs related to research and development activities that are not classified under specific program-level or indirect categories. This often captures ancillary lab expenses, specialized equipment maintenance, or project-specific overheads. Tracking this provides visibility into the operational complexity and non-programmatic spending required to sustain R&D efforts.
Ask your AI about Immunome's business segments — other direct research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude